TABLAS
Observational Prospective Case-control Study on Prevalence and Impact of Subclinical Hyperthyroidism in Patients Undergoing Atrial Fibrillation Ablation
Sponsor study identifier
observational
327
1 country
2
Study Start
February 2013
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
October 2015
Actual (reported)Study Completion
November 2015
Actual (reported)Overt hyperthyroidism (so-called "goiter" in lay language) is a hormonal disturbance that is known to increase the risk of atrial fibrillation (a common heart arrhythmia with potentially severe consequences) in some patients. Previous research has indicated that even slight elevations in thyroid hormone levels - so called subclinical hyperthyroidism - may increase this risk. When atrial fibrillation and overt hyperthyroidism are found simultaneously in a patient, the hormonal imbalance must be treated first in order to later resolve the arrhythmia. It is unclear whether this strategy holds true for subclinical hyperthyroidism. Our two hypotheses are: 1) Subclinical hyperthyroidism is more prevalent in patients admitted for atrial fibrillation ablation than in the population as a whole, and 2) Patients with subclinical hyperthyroidism and atrial fibrillation benefit less from ablation than others. As a control group, we have chosen patients admitted for ablation of AV-nodal Reentry Tachycardia at the same clinics as the cases. No correlation has ever been shown between AV-nodal Reentry Tachycardia and hyperthyroidism.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 2015
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 2013
Date type not reportedThis date has not been verified as actual or estimated.
February 5, 2013
Actual (reported)February 12, 2013
Actual (reported)October 2015
Actual (reported)November 2015
Actual (reported)Prevalence of subclinical hyperthyroidism in patients undergoing atrial fibrillation ablation
1 day (Measured upon inclusion)
Recurrent atrial fibrillation after ablation
6 months
Patients with atrial fibrillation undergoing ablation
Patients with AV-Nodal Reentry Tachycardia undergoing ablation
Patients with atrial fibrillation (cases) or AV-nodal reentry tachycardia (controls)
Stockholm Arrhythmia Center
Stockholm, 11861, Sweden
Hjärtkliniken, Karolinska Universitetssjukhuset Huddinge
Stockholm, 14147, Sweden
Mårten Rosenqvist, Professor
Karolinska Institutet, Institutionen för kliniska vetenskaper vid Danderyds sjukhus
327 participants (actual enrollment reported by the registry).
First Submitted
February 5, 2013
First Posted
February 12, 2013
Study Start
February 2013
Date type not reportedThis date has not been verified as actual or estimated.
Cryoballoon Ablation in Patients With Longstanding Persistent Atrial Fibrillation
Contact the study team to confirm eligibility.
Primary Completion
October 2015
Actual (reported)Study Completion
November 2015
Actual (reported)Last Updated
January 20, 2016
Record last verified: 2016-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: